Xeris Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $71,539 | $60,119 | $60,099 | $54,268 |
Gross Profit | 56,930 | 51,391 | 50,621 | 40,675 |
EBITDA | 8,594 | 1,228 | 5,723 | -8,152 |
EBIT | 5,430 | -1,915 | 2,590 | -11,276 |
Net Income | -1,928 | -9,220 | -5,113 | -15,738 |
Net Change In Cash | 71,539 | 60,119 | 60,099 | 54,268 |
Free Cash Flow | 10,044 | -10,044 | 1,755 | -8,392 |
Cash | 59,285 | 58,440 | 71,621 | 59,232 |
Basic Shares | 155,972 | 152,445 | 149,092 | 148,994 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $203,070 | $163,914 | $110,248 | $49,590 |
Gross Profit | 166,238 | 135,269 | 87,614 | 36,272 |
EBITDA | -13,994 | -23,735 | -69,314 | -113,666 |
EBIT | -26,619 | -36,895 | -81,982 | -115,545 |
Net Income | -54,836 | -62,255 | -94,660 | -122,725 |
Net Change In Cash | 203,070 | 163,914 | 110,248 | 49,590 |
Free Cash Flow | -37,849 | -49,286 | -103,415 | -96,620 |
Cash | 71,621 | 67,449 | 121,966 | 67,271 |
Basic Shares | 146,773 | 137,674 | 135,628 | 79,027 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.01 |
2025-03-31 | -$0.06 |
2024-12-31 | -$0.03 |
